CTOs on the Move

Mabtech Inc

www.mabtech.com

 
Mabtech Inc is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.mabtech.com
  • 3814 West St Ste 112
    Cincinnati, OH USA 45227
  • Phone: 513.871.4500

Executives

Name Title Contact Details

Similar Companies

DiaKine Therapeutics

DiaKine Therapeutics is a Charlottesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cyagen Biosciences

Cyagen Biosciences is a 400-employee company headquartered in Santa Clara, California, with additional locations in Germany, Japan and China. Cyagen is the world`s largest provider of custom-engineered mouse and rat models. Cyagen`s services have become well known for their top quality, full guarantee, and competitive prices.

Alzheon

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders.

Sonde Health

Sonde Health is a digital medicine company developing a voice-based technology platform with the potential to transform the way we monitor and diagnose mental and physical health.

Annexon Biosciences

Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders of the body, brain and eye. The company`s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration) and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.